Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT05633615 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

396

Enrollment

NETWORK

Sponsor class

Conditions

Diffuse Large B-Cell Lymphoma
Grade 3b Follicular Lymphoma
Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Transformed Follic Lymph to Diff Large B-Cell Lymphoma
Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma

Interventions

BIOLOGICAL: Axicabtagene Ciloleucel
PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
DRUG: Cyclophosphamide
DRUG: Fludarabine
BIOLOGICAL: Lisocabtagene Maraleucel
BIOLOGICAL: Mosunetuzumab
OTHER: Patient Observation
DRUG: Polatuzumab Vedotin
PROCEDURE: Positron Emission Tomography
BIOLOGICAL: Tisagenlecleucel

Sponsor

SWOG Cancer Research Network

Collaborators

[object Object]
[object Object]